Crinetics Pharmaceuticals (CRNX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on the stock and has a $82.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Cory Jubinville, PhD’s rating is based on Crinetics Pharmaceuticals’ strategic advancements and promising pipeline. The company is nearing a significant milestone with the PDUFA date for paltusotine in acromegaly set for September 25 and a CHMP opinion expected in the first half of 2026. This positions Crinetics closer to becoming an integrated commercial-stage entity.
Furthermore, Crinetics has showcased its potential through an in-person R&D Day, highlighting three early-stage programs targeting GPCRs in endocrinology and oncology. These programs, including treatments for Graves’ disease, ADPKD, and neuroendocrine tumors, demonstrate the company’s strength in endocrinology and its ambition to address broader commercial markets with high unmet needs. The company’s ability to advance mechanism-driven therapies through late-stage development, as seen with paltusotine and atumelnant, further supports the Buy rating.
In another report released on June 27, Leerink Partners also reiterated a Buy rating on the stock with a $80.00 price target.